This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
After two decades of engineering, over $10 billion, and a series of delays, the most powerful telescope built by NASA is finally scheduled to launch on Saturday. The James Webb Space Telescope was built to provide a fresh look at the universe by detecting light that is invisible to the human eye and to reveal new information about the universe's oldest stars and galaxies. Lou Strolger, observatory scientist and deputy head of instruments division, space telescope, joins Cheddar News.
Carlo and Baker kick off the weirdest week of the year with all the news you missed over the holiday weekend, including calls for the CDC to shorten its isolation window as Omicron sweeps through the country.
The 2022 Winter Olympics will be without some of hockey's biggest players. The NHL and the NHL Player's Association have agreed to not participate in the men's hockey tournament at the Games in Beijing next year. The league has been forced to postpone some games because of a rise in COVID-19 cases among players. Washington Post sports reporter Samantha Pell joins Cheddar News' Closing Bell to discuss what this could mean for the Winter Olympics and the sport of hockey.
The National Highway Traffic Safety Administration has opened a formal investigation into Tesla. The agency is looking into about 580,000 Tesla vehicles, and a feature called 'Passenger Play' which allows drivers to play video games on the center touch screen. The feature previously only worked when a vehicle was in park; but, the NHTSA says it has confirmed that the feature has been available while vehicles are in motion since December of 2020. iSeeCars.com executive analyst Karl Brauer joins Cheddar News' Closing Bell to discuss.
Baron Davis and Kate Hudson want you to bring cannabis home for the holidays. The cannabis-infused seltzer brand Cann released a new spot featuring the actress and former NBA player. The campaign comes hand in hand with Cann's launch of a new holiday bundle, which includes its product with Hudson's King Street Vodka. Davis and Hudson are also Cann investors. Cheddar cannabis reporter Chloe Aiello spoke to Davis about his involvement with the company and its new campaign.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
